These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22232075)

  • 1. A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major.
    Elalfy MS; Massoud W; Elsherif NH; Labib JH; Elalfy OM; Elaasar S; von Mackensen S
    Pediatr Blood Cancer; 2012 Jun; 58(6):910-5. PubMed ID: 22232075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β-thalassemia, in routine care settings in Western Greece.
    Goulas V; Kouraklis-Symeonidis A; Manousou K; Lazaris V; Pairas G; Katsaouni P; Verigou E; Labropoulou V; Pesli V; Kaiafas P; Papageorgiou U; Symeonidis A
    Qual Life Res; 2021 Feb; 30(2):467-477. PubMed ID: 32920766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic burden of infused iron chelation therapy in the United States.
    Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
    Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study.
    Scalone L; Mantovani LG; Krol M; Rofail D; Ravera S; Bisconte MG; Borgna-Pignatti C; Borsellino Z; Cianciulli P; Gallisai D; Prossomariti L; Stefàno I; Cappellini MD
    Curr Med Res Opin; 2008 Jul; 24(7):1905-17. PubMed ID: 18507891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument.
    Rofail D; Abetz L; Viala M; Gait C; Baladi JF; Payne K
    Value Health; 2009; 12(1):109-17. PubMed ID: 18637142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.
    Taher A; Al Jefri A; Elalfy MS; Al Zir K; Daar S; Rofail D; Baladi JF; Habr D; Kriemler-Krahn U; El-Beshlawy A
    Acta Haematol; 2010; 123(4):220-5. PubMed ID: 20424435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major.
    Christoforidis A; Perifanis V; Athanassiou-Metaxa M
    Br J Haematol; 2006 Oct; 135(2):271-2. PubMed ID: 16965387
    [No Abstract]   [Full Text] [Related]  

  • 10. An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial.
    Rofail D; Viala M; Gater A; Abetz-Webb L; Baladi JF; Cappellini MD
    Adv Ther; 2010 Aug; 27(8):533-46. PubMed ID: 20652657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and complications of thalassemia major in Guangxi, Southern China.
    Yin XL; Wu ZK; He YY; Zhou TH; Zhou YL; Zhang XH
    Pediatr Blood Cancer; 2011 Dec; 57(7):1174-8. PubMed ID: 21394896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K; Tzoumari I; Pappa C
    Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
    Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
    Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
    Chan GC; Ng DM; Fong DY; Ha SY; Lau YL
    Am J Hematol; 2004 Aug; 76(4):398-404. PubMed ID: 15282678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy.
    Horodniceanu EG; Bal V; Dhatt H; Carter JA; Huang V; Lasch K
    Health Qual Life Outcomes; 2017 Jun; 15(1):129. PubMed ID: 28645270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.
    Di Maggio R; Maggio A
    Br J Haematol; 2017 Sep; 178(5):676-688. PubMed ID: 28439891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Validity and reliability of a new questionnaire on patient satisfaction in rehabilitative therapy].
    Franchignoni F; Benevolo E; Ottonello M; Tesio L; Battaglia MA
    Minerva Med; 1998 Mar; 89(3):57-64. PubMed ID: 9575331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.